Home › Funds › BVF INC/IL › FDMT
BVF INC/IL position in FDMT
4D MOLECULAR THERAPEUTICS IN · Health Care
BVF INC/IL reported holding 2,879,289 shares of FDMT (4D MOLECULAR THERAPEUTICS IN) in its Q2 2026 13F filing — a position valued at US$38.3M, representing 0.98% of its reported portfolio and ranking #26 among its reported holdings. BVF INC/IL has disclosed FDMT holdings in 12 of the last 12 reported quarters, going back to Q3 2023.
Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR
How BVF INC/IL's FDMT position evolved
BVF INC/IL first disclosed a stake in FDMT in Q3 2023 at 4,007,413 shares (US$51.0M). The position peaked in Q1 2024 at 3,922,413 shares, worth US$125.0M. Across 12 filings, BVF INC/IL increased the stake 3 time(s), trimmed it 3 time(s) and left it unchanged 5 time(s). The most recent filing (Q2 2026) shows 2,879,289 shares valued at US$38.3M. Notable position changes include a 88% increase in Q3 2024 (shares fell 48% over the following quarter), a 64% trim in Q4 2024 (shares fell 42% over the following quarter), a 71% increase in Q1 2025 (shares rose 15% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q3 2023 | 4.01M | $51.01M | New |
| Q4 2023 | 4.01M | $81.19M | Hold |
| Q1 2024 | 3.92M | $124.97M | Reduce |
| Q2 2024 | 3.92M | $82.33M | Hold |
| Q3 2024 | 7.38M | $79.81M | Add |
| Q4 2024 | 2.67M | $14.88M | Reduce |
| Q1 2025 | 4.56M | $14.73M | Add |
| Q2 2025 | 4.63M | $17.17M | Add |
| Q3 2025 | 4.63M | $40.23M | Hold |
| Q4 2025 | 4.63M | $34.72M | Hold |
| Q1 2026 | 2.88M | $26.81M | Reduce |
| Q2 2026 | 2.88M | $38.29M | Hold |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About FDMT and 13F data
FDMT (4D MOLECULAR THERAPEUTICS IN) is a Health Care company. 35 other funds we track also report a position in FDMT — the largest reported positions include RA CAPITAL MANAGEMENT, L.P. (US$67.2M), Novo Holdings A/S (US$43.2M), Trails Edge Capital Partners, LP (US$29.6M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding FDMT
- RA CAPITAL MANAGEMENT, L.P. 5.05M sh · $67.16M · Q2 2026
- Novo Holdings A/S 3.25M sh · $43.21M · Q2 2026
- Trails Edge Capital Partners, LP 2.23M sh · $29.63M · Q2 2026
- ARMISTICE CAPITAL, LLC 2.00M sh · $26.60M · Q2 2026
- Evergreen Quality Fund GP, Ltd. 951.47K sh · $12.65M · Q2 2026
- Parkman Healthcare Partners LLC 948.18K sh · $12.61M · Q2 2026
- DIADEMA PARTNERS LP 571.11K sh · $7.60M · Q2 2026
- ACUTA CAPITAL PARTNERS, LLC 507.80K sh · $6.75M · Q2 2026
- Catalio Capital Management, LP 471.25K sh · $6.27M · Q2 2026
- Opaleye Management Inc. 334.44K sh · $4.45M · Q2 2026
FAQ
How long has BVF INC/IL held FDMT?
BVF INC/IL has disclosed FDMT holdings in 12 of the last 12 reported quarters, going back to Q3 2023.
What is BVF INC/IL's current position in FDMT?
As of Q2 2026, BVF INC/IL holds 2.88M shares of FDMT (4D MOLECULAR THERAPEUTICS IN), valued at $38.29M, representing 0.98% of its reported portfolio and ranking #26.
Has BVF INC/IL been buying or selling FDMT?
In the latest 13F filing (Q2 2026), BVF INC/IL held unchanged its position in FDMT. The position peaked in Q1 2024 at 3.92M shares.
Which other funds hold FDMT?
Other major institutional holders of FDMT include RA CAPITAL MANAGEMENT, L.P., Novo Holdings A/S, Trails Edge Capital Partners, LP, among 35 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.